Artisan Partners Limited Partnership Acquires 1,048,692 Shares of Veracyte, Inc. $VCYT

Artisan Partners Limited Partnership raised its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT) by 16.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,370,467 shares of the biotechnology company’s stock after acquiring an additional 1,048,692 shares during the quarter. Artisan Partners Limited Partnership owned about 9.32% of Veracyte worth $253,028,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Royal Bank of Canada grew its position in shares of Veracyte by 23.3% in the first quarter. Royal Bank of Canada now owns 28,712 shares of the biotechnology company’s stock valued at $852,000 after purchasing an additional 5,435 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Veracyte by 12.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 195,793 shares of the biotechnology company’s stock worth $5,805,000 after purchasing an additional 21,330 shares in the last quarter. Jane Street Group LLC boosted its stake in Veracyte by 94.7% in the 1st quarter. Jane Street Group LLC now owns 216,909 shares of the biotechnology company’s stock worth $6,431,000 after purchasing an additional 105,499 shares during the period. Intech Investment Management LLC grew its holdings in Veracyte by 54.1% during the 1st quarter. Intech Investment Management LLC now owns 42,762 shares of the biotechnology company’s stock valued at $1,268,000 after buying an additional 15,017 shares in the last quarter. Finally, AlphaQuest LLC increased its position in shares of Veracyte by 1,279.9% during the second quarter. AlphaQuest LLC now owns 8,031 shares of the biotechnology company’s stock valued at $217,000 after buying an additional 7,449 shares during the period.

Key Stories Impacting Veracyte

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Q4 beat — Veracyte reported Q4 revenue of about $140.6M (up ~18.5% y/y) and EPS of $0.53, topping consensus; management highlighted improved margins and a big jump in profitability versus year-ago quarter. Veracyte Q4 Earnings Beat
• Positive Sentiment: Profitability & cash improved materially — operating profit, net income and cash from operations rose substantially year-over-year and cash & equivalents increased (QuiverQuant summary), supporting a stronger financial profile. QuiverQuant Financial Snapshot
• Positive Sentiment: 2026 guidance and product cadence — management outlined 2026 revenue growth of 10%–13% and plans to advance MRD efforts and Prosigna launches, giving investors visibility on growth drivers beyond core testing. Veracyte 2026 Outlook
• Positive Sentiment: Analyst upgrade/price-target lift — Needham bumped its price target (to $48) and maintains a Buy, adding upside from current levels and likely helping investor sentiment. Benzinga Analyst Note
• Neutral Sentiment: Full earnings materials & call transcripts available — management commentary and the earnings deck/transcript provide detail on revenue mix and pipeline; useful for modeling but not a surprise after the print. Earnings Call Transcript
• Negative Sentiment: Insider selling and mixed institutional flows — recent data show substantial insider sell activity and large institutional position changes (some big sellers), which could temper enthusiasm despite the beat. QuiverQuant Insider & Institutional Activity

Analysts Set New Price Targets

A number of equities analysts have recently commented on VCYT shares. Needham & Company LLC raised their price objective on shares of Veracyte from $44.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday. Guggenheim increased their target price on shares of Veracyte from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Zacks Research upgraded shares of Veracyte from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 11th. Canaccord Genuity Group increased their price objective on Veracyte from $40.00 to $43.00 and gave the stock a “hold” rating in a research report on Wednesday, November 5th. Finally, Wall Street Zen raised Veracyte from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Veracyte Trading Up 8.6%

NASDAQ VCYT opened at $38.80 on Friday. The firm has a market cap of $3.07 billion, a PE ratio of 46.74 and a beta of 1.91. Veracyte, Inc. has a 1-year low of $22.61 and a 1-year high of $50.71. The stock has a 50-day moving average of $39.97 and a 200-day moving average of $37.78.

Veracyte (NASDAQ:VCYT) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.12. Veracyte had a return on equity of 8.19% and a net margin of 12.83%.The business had revenue of $140.64 million for the quarter, compared to analysts’ expectations of $135.79 million. During the same period in the previous year, the firm earned $0.06 EPS. The business’s quarterly revenue was up 18.5% on a year-over-year basis. As a group, equities research analysts forecast that Veracyte, Inc. will post 0.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Rebecca Chambers sold 13,278 shares of Veracyte stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $46.84, for a total value of $621,941.52. Following the transaction, the chief financial officer directly owned 109,496 shares of the company’s stock, valued at $5,128,792.64. The trade was a 10.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc Stapley sold 7,668 shares of the stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $47.09, for a total transaction of $361,086.12. Following the sale, the chief executive officer directly owned 318,603 shares of the company’s stock, valued at $15,003,015.27. The trade was a 2.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 54,385 shares of company stock valued at $2,483,179 over the last quarter. Company insiders own 1.40% of the company’s stock.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.